Everything dog owners need to know about Simparica Trio: what it does, how it works, real FDA-verified risks, the neurological warning, whether it’s right for your dog, and honest comparisons with Bravecto and NexGard.
Simparica Trio is a once-monthly prescription chewable tablet manufactured by Zoetis and FDA-approved on February 27, 2020 (NADA 141-521). It combines three active pharmaceutical ingredients — sarolaner (isoxazoline; fleas and ticks), moxidectin (macrocyclic lactone; heartworm prevention), and pyrantel pamoate (roundworms and hookworms) — making it the first combination isoxazoline product ever approved for dogs in the United States. As of Q4 2024, it has been used in more than 15 million dogs. In April 2025, the FDA approved a fourth indication: prevention of flea tapeworm (Dipylidium caninum) infections. Simparica Trio is FDA-approved as safe and effective — but the FDA has separately issued an explicit public alert that the isoxazoline class (which includes sarolaner) is associated with neurologic adverse reactions including muscle tremors, ataxia, and seizures in some dogs, even without a prior history of neurological disease. BestiePaws.com™ presents the complete picture here so you can make an informed decision with your veterinarian.
-
1
What are the negative effects of Simparica Trio? The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. More serious but rare: neurological effects — muscle tremors, incoordination (ataxia), and seizures — associated with the isoxazoline class (sarolaner). These can occur even in dogs with no prior neurological history. The FDA has issued a formal public alert about this risk for all isoxazoline products.The FDA’s formal adverse event communication confirms that isoxazoline products including Simparica Trio “have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures in some dogs.” Critically, “seizures may occur in animals without a prior history.” The official Simparica Trio prescribing information (DailyMed/NIH) states: “Use with caution in dogs with a history of seizures or neurologic disorders.” Additional adverse reactions documented in clinical trials and the FDA’s approval documents include: lethargy, anorexia, otitis externa (ear infection), pruritus (itching), polyuria (more frequent urination), hyperactivity, and polydipsia (increased water intake). A PMC 2023 peer-reviewed study confirmed the product was generally well tolerated in heartworm-positive dogs at 1× and 3× the recommended dose, with emesis (vomiting) at low frequency and no severe hypersensitivity reactions observed over a 3-month study period.
-
2
Is Simparica Trio effective? Yes — it is FDA-approved as effective and is backed by multiple peer-reviewed clinical studies. It kills fleas within 4 hours and begins killing deer ticks within 8 hours. It covers 6 tick species (the most of any comparable combination product), prevents heartworm disease, and treats roundworms and hookworms — all in a single monthly chew. It has been used in 15+ million dogs as of Q4 2024.A randomized controlled field study published in PMC (2020, Kryda et al.) across 18 U.S. general veterinary practices confirmed Simparica Trio’s safety and efficacy against natural flea infestations in client-owned dogs. The FDA’s NADA 141-521 approval documentation confirms the product met all efficacy standards for each of its indications across the three active ingredients: sarolaner for fleas and six tick species, moxidectin for heartworm prevention (Dirofilaria immitis larvae), and pyrantel pamoate for roundworm (Toxocara canis, Toxascaris leonina) and hookworm (Ancylostoma caninum, Uncinaria stenocephala) treatment. The April 2025 FDA supplement added flea tapeworm (Dipylidium caninum) prevention as a fifth indication — the only combination parasiticide with this indication in the U.S. Zoetis’s comparison data (2025) confirms Simparica Trio covers 6 tick species vs. NexGard Plus’s 5 and Bravecto’s 4.
-
3
Is Simparica Trio a pesticide? Technically, sarolaner (one of its active ingredients) belongs to the isoxazoline chemical class, which includes compounds used as pesticides. However, Simparica Trio as a veterinary chewable tablet is classified and regulated as a prescription animal drug by the FDA — not as a pesticide by the EPA. It requires a veterinarian’s prescription to purchase in the United States.The FDA regulates Simparica Trio under the Federal Food, Drug, and Cosmetic Act as a new animal drug (NADA 141-521) — not under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which is how the EPA regulates topical pesticide products. The FDA’s fact sheet on isoxazolines explicitly notes: “Some flea and tick products are regulated by the FDA and some are regulated by the Environmental Protection Agency.” Products in chewable/oral tablet form for flea and tick control are generally regulated by the FDA. Topical spot-on treatments containing insecticides for the same purpose are often regulated by the EPA. The mechanism of sarolaner — inhibiting GABA receptor and glutamate receptor function to cause neuromuscular paralysis in parasites — is indeed a pesticide mechanism. But the delivery vehicle (a prescription oral chewable) places it firmly in the FDA’s drug category for regulatory purposes.
-
4
What are the risks of Simparica Trio? Primary risks: (1) Neurological reactions — tremors, ataxia, seizures — associated with the isoxazoline class; risk is elevated in dogs with a personal or breed history of seizures or neurological disorders. (2) GI effects — vomiting and diarrhea are the most common. (3) Not evaluated in breeding, pregnant, or lactating dogs. (4) Not effective against adult heartworms — dogs must be tested first.The FDA’s post-marketing surveillance data, collected after the original approvals of isoxazoline products, prompted the agency to issue a formal Drug Safety Communication specifically about neurologic adverse events. This is not a label warning that was added after a recall — it is a proactive public health alert. Zoetis confirmed in their own public statement (2022): “Simparica Trio contains sarolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders.” The full prescribing information at SimparicaTrioPI.com confirms there are no known contraindications, but “use with caution” is the formal guidance for dogs with seizure history. Additional risk: Simparica Trio is not effective against adult Dirofilaria immitis (adult heartworms) — it prevents new infections from larvae but does not treat existing adult worm infestations. Dogs must be tested for heartworm before starting. Giving Simparica Trio to a heartworm-positive dog without treating the adult worms first can cause dangerous thromboembolic reactions as microfilariae die rapidly.
-
5
Is Simparica Trio safe for small dogs? Simparica Trio is approved for use in dogs 8 weeks of age and older weighing at least 2.8 pounds — the lowest minimum weight of any comparable combination parasiticide product (NexGard Plus requires ≥4 lbs; Bravecto requires ≥4.4 lbs). It comes in 6 weight-appropriate tablet sizes. Small breed owners should be aware that the neurological risk warning applies equally regardless of size.Simparica Trio’s 2.8-pound minimum weight threshold is a deliberate advantage for toy breeds, very small dogs, and small puppies. The six tablet sizes — covering weight ranges from 2.8–5.5 lbs, 5.6–11 lbs, 11.1–22 lbs, 22.1–44 lbs, 44.1–88 lbs, and 88.1–132 lbs — are calibrated to deliver the correct minimum dosage (sarolaner 1.2 mg/kg; moxidectin 24 µg/kg; pyrantel pamoate 5 mg/kg) at each weight range. For very small dogs, using the correct weight-appropriate tablet is critical — giving a larger-sized tablet to a small dog can result in overdose. The FDA approval documentation confirms the dosing is weight-per-kilogram so all six tablet sizes deliver equivalent drug exposure per body weight. The neurological caution (seizures reported even without prior history) applies to small dogs equally — breed predisposition to neurological conditions (e.g., small breeds prone to collapsing trachea or MVD should be discussed with a vet before starting).
-
6
Is Simparica Trio vs. Bravecto — which is better? Simparica Trio is better if you want heartworm prevention + roundworm/hookworm treatment combined with flea and tick protection in one monthly dose. Bravecto is better if you want longer-lasting protection (12 weeks per dose vs. monthly), no need for heartworm prevention in the same product, and proven safety in breeding/pregnant/lactating dogs. Both are FDA-approved; both are isoxazoline class.Key comparison differences: Simparica Trio covers 6 tick species; Bravecto covers 4. Simparica Trio requires monthly dosing; Bravecto is given every 12 weeks — only 4 doses per year instead of 12. Bravecto has established safety data for use in breeding, pregnant, and lactating dogs — Simparica Trio does not. For owners whose dog takes a separate heartworm preventative, Bravecto may be preferred (fewer total medications). For owners who want everything in one monthly dose — heartworm, fleas, ticks, and intestinal parasites — Simparica Trio is the more comprehensive single-product option. BestiePaws.com™ recommends discussing with your vet which approach fits your dog’s specific health profile and regional parasite risk. Both require a veterinarian’s prescription in the United States.
-
7
Is Simparica Trio safe for puppies? Yes — Simparica Trio is FDA-approved for puppies 8 weeks of age and older weighing at least 2.8 pounds. This is one of its distinct advantages over Bravecto (approved from 6 months) for very young dogs. The same neurological caution and “use with caution in dogs with seizure history” applies to puppies as with adult dogs.The FDA’s NADA 141-521 approval and all subsequent label supplements confirm the minimum age of 8 weeks and minimum weight of 2.8 lbs as the starting point for safe use. This means puppies can begin parasite prevention — including heartworm protection — at 8 weeks, which aligns with when puppies typically begin their first veterinary visits and vaccine schedules. Starting heartworm prevention early is important: the American Heartworm Society recommends year-round prevention starting as early as possible. Pyrantel pamoate, one of the three active ingredients, is particularly relevant for puppies because roundworms and hookworms are very common in young dogs, many of whom acquire infections from their mothers. The combination of heartworm prevention, roundworm/hookworm treatment, and flea/tick control in a single monthly chew starting at 8 weeks of age is a practical advantage for new puppy owners.
-
8
Is Simparica Trio safe for humans? Simparica Trio is formulated exclusively for dogs and must be kept out of reach of children. There are no documented cases of human toxicity from incidental contact with a single tablet. However, the active ingredients — particularly moxidectin — are not safe for human ingestion. In case of accidental human ingestion, contact Poison Control at 1-800-222-1222 immediately.The official prescribing information states: “Not for use in humans. Keep this and all drugs out of reach of children.” The pork-liver flavoring that makes the tablets palatable to dogs also makes them potentially appealing to children — this is a real-world safety concern in households with young children. Moxidectin, one of the three active ingredients, is a macrocyclic lactone that affects chloride channel neurotransmission — its safety profile in humans is very different from its profile in healthy adult dogs. Moxidectin has been studied for human use at much lower doses in parasitology research, but the veterinary tablet concentration is not appropriate for humans. Pyrantel pamoate, while used in some over-the-counter human dewormers at different concentrations, should not be supplemented through veterinary products. If a child or adult ingests a Simparica Trio tablet, call U.S. Poison Control at 1-800-222-1222 immediately — do not wait for symptoms.
-
9
Which is safer: NexGard or Simparica Trio? Both NexGard Plus and Simparica Trio are FDA-approved prescription isoxazoline products with comparable safety profiles. Both carry the same neurological warning (tremors, ataxia, seizures). Simparica Trio additionally contains moxidectin and pyrantel. Neither has been evaluated in breeding/pregnant/lactating dogs. No clinical evidence shows either is categorically safer than the other for the general dog population.NexGard’s active ingredient is afoxolaner, while Simparica Trio uses sarolaner — both are isoxazoline class compounds, both carry the FDA’s neurological adverse event alert. The same FDA fact sheet covers both products equally. The key practical differences: Simparica Trio covers 6 tick species vs. NexGard Plus’s 5. Simparica Trio’s minimum weight is 2.8 lbs vs. NexGard Plus’s 4 lbs. Both are monthly treatments. Both require veterinary prescription. Both have similar GI adverse reaction profiles (vomiting, diarrhea as most common reported events). For dogs with a history of seizures or neurological disease, neither isoxazoline product is preferred without explicit veterinary guidance — both carry the same class warning. Your veterinarian’s knowledge of your individual dog’s health history, breed predispositions, and local parasite prevalence should drive the selection, not head-to-head safety rankings from general comparison articles.
-
10
Is Simparica Trio really necessary, and do vets recommend it? Heartworm prevention, flea control, and tick protection are genuinely medically necessary for most dogs in the U.S. — heartworm disease is fatal if untreated and is present in all 50 states. Whether Simparica Trio specifically is the right product depends on your dog’s health, age, breed, and regional parasite risk. Most U.S. veterinarians do recommend some form of comprehensive parasite prevention; many do recommend Simparica Trio for healthy adult dogs.The American Heartworm Society (AHS) recommends year-round heartworm prevention for all dogs in the United States — heartworm-transmitting mosquitoes are active in all 50 states, and indoor dogs are also at risk. The CDC lists Lyme disease (transmitted by black-legged ticks, one of the 6 species Simparica Trio covers) as the most common vector-borne disease in the U.S. The value of Simparica Trio comes from consolidating what would otherwise be multiple separate monthly medications (heartworm preventative + flea/tick treatment + intestinal dewormer) into a single monthly chew — this simplifies compliance and reduces the chance of missed doses. Vets frequently recommend it for this reason. The cases where a vet might NOT recommend Simparica Trio: dogs with a personal or breed history of seizures, dogs in areas with very low tick prevalence (where the tick coverage adds less value), breeding females, or owners who prefer topical treatments. Zoetis offers a 100% satisfaction guarantee through the prescribing veterinarian.
Sources: FDA fda.gov (NADA 141-521 approval Feb 27 2020; new indication April 8 2025; isoxazoline neurological alert: tremors/ataxia/seizures; seizures without prior history; sarolaner first approved 2016; moxidectin 1997; pyrantel pamoate 1977); DailyMed NIH (sarolaner: GABA receptor + glutamate receptor inhibition; moxidectin: chloride channel disruption; pyrantel: GI nematocide; “use with caution seizure history”; no known contraindications); PMC 2023 Mathur et al. (well tolerated heartworm-positive dogs 1× 3× dose; emesis low frequency; no severe reactions); PMC 2020 Kryda et al. (18 U.S. vet practices; RCT; safe+efficacious vs natural flea); Zoetis zoetispetcare.com (6 tick species; fleas within 4hrs; deer ticks within 8hrs; pork-liver flavored; $9.3B revenue 2024; 15M+ dogs Q4 2024; April 2025 flea tapeworm new indication; 100% satisfaction guarantee); budgetpetworld.com Mar 2025 (Simparica Trio 6 species, NexGard 5, Bravecto 4; minimum weights: 2.8/4/4.4 lbs); BestiePaws.com™ bestiepaws.com (first combo isoxazoline U.S.; Asian longhorned Nov 2024; MDR1 safety note; Credelio Quattro praziquantel)
Sources: BestiePaws.com™ (15M+ dogs Q4 2024; first combo isoxazoline; Asian longhorned Nov 2024); Zoetis zoetispetcare.com (6 tick species; fleas 4hrs; deer ticks 8hrs); FDA NADA 141-521 April 2025 supplement (flea tapeworm new indication; April 8 2025); Zoetis comparison chart (vs NexGard Plus 5 species; vs Bravecto 4 species); PMC 2020 Kryda et al. (≥96.2% flea reduction within 8hrs; >95.6% monthly study)
The FDA has issued a formal Drug Safety Communication alerting pet owners and veterinarians that isoxazoline products — including Simparica Trio — are associated with neurologic adverse reactions, including muscle tremors, ataxia (loss of coordination), and seizures in some dogs. Seizures have been reported in dogs with no prior history of neurological disease. The FDA considers the product safe and effective for most dogs — but says pet owners and vets should “take this risk into account when making prescribing and treatment decisions, particularly for animals with a history of seizures or neurological disorders.” Source: fda.gov/animal-veterinary/animal-health-literacy/fact-sheet-pet-owners.
Sources: FDA fda.gov (NADA 141-521; neurological Drug Safety Communication; isoxazoline fact sheet; tremors/ataxia/seizures; seizures without prior history; sarolaner 2016; moxidectin 1997; pyrantel 1977); Zoetis/DailyMed NIH (prescribing information: not evaluated breeding/pregnant/lactating; vomiting/diarrhea most common; no contraindications; use caution seizure history; not adulticidal; test required before starting); PMC 2023 Mathur et al. (well tolerated heartworm-positive 1×/3× dose; emesis low frequency; no severe reactions); PMC 2020 Kryda et al. (18 U.S. practices; RCT; safe+efficacious natural fleas); BestiePaws.com™ bestiepaws.com (15M+ dogs Q4 2024; Asian longhorned Nov 2024 expansion; H. longicornis 19+ states; Credelio Quattro praziquantel comparison; Bravecto pregnant dogs safe); budgetpetworld.com Mar 2025 (6/5/4 tick species; minimum weights 2.8/4/4.4 lbs; monthly vs. 12-week Bravecto); Zoetis zoetispetcare.com (pork-liver flavored; 100% satisfaction guarantee; 6 tablet sizes)
There are two categories of negative effects to understand clearly. Common (reported in clinical trials): Vomiting and diarrhea are the most frequently reported adverse reactions. Zoetis’s own clinical trial data confirms this. Additional reactions documented in the FDA approval include lethargy, anorexia, ear infections (otitis externa), itching (pruritus), more frequent urination (polyuria), hyperactivity, and increased water intake (polydipsia). Serious but rare (FDA-confirmed class warning): Neurological effects — muscle tremors, incoordination (ataxia), and seizures — have been reported across the isoxazoline class, which includes sarolaner, one of the three active ingredients in Simparica Trio. The FDA has formally stated these can occur even in dogs with no prior history of neurological disease. The FDA’s explicit guidance: “Use with caution in dogs with a history of seizures or neurologic disorders.” If your dog experiences any neurological signs after taking Simparica Trio — shaking, stumbling, unresponsiveness, or a seizure — contact your veterinarian immediately and report the event to Zoetis (1-888-963-8471) and the FDA’s MedWatch for veterinary products. The FDA considers the product safe and effective for the majority of dogs — the neurological risk is real but appears to affect a small subset of the treated population.
Yes — it is FDA-approved as effective and its efficacy has been confirmed in multiple peer-reviewed randomized controlled studies conducted in U.S. veterinary practices. Its effectiveness data by indication: Fleas: Begins killing within 4 hours; ≥96.2% reduction in live fleas within 8 hours in laboratory studies; over 95.6% reduction in adult fleas in simulated home-environment studies with re-infestations over three months (PMC 2020). Ticks: Begins killing deer ticks within 8 hours; covers 6 species — more than any comparable combination product currently available. Heartworm: Moxidectin prevents Dirofilaria immitis larval development — it is one of the most effective preventatives available. It does NOT treat adult heartworms already present. Intestinal parasites: Pyrantel pamoate treats and controls immature and adult roundworms and hookworms — pathogens particularly common in young dogs and in dogs with regular outdoor or environmental exposure. As of Q4 2024, Simparica Trio has been used to protect more than 15 million dogs — a real-world scale that reflects both its efficacy and its broad veterinary endorsement.
No clinical evidence establishes one as categorically safer than the other. Both NexGard/NexGard Plus (afoxolaner, Boehringer Ingelheim) and Simparica Trio (sarolaner, Zoetis) are isoxazoline class products, and the FDA’s neurological adverse event alert applies equally to both. The same FDA fact sheet covers both. The safety of each product for an individual dog depends far more on that dog’s specific health history, breed predispositions, and current medications than on which brand is used. Key practical distinctions: Simparica Trio contains two additional active ingredients (moxidectin and pyrantel) that NexGard does not — these add efficacy but also add pharmacological complexity for dogs on certain other medications. Simparica Trio covers 6 tick species vs. NexGard Plus’s 5. Simparica Trio’s minimum weight is 2.8 lbs vs. NexGard Plus’s 4 lbs. If your dog has a history of seizures: neither isoxazoline product should be used without an explicit veterinary risk-benefit discussion. If your dog needs a product safe for breeding or pregnancy: Bravecto has established safety data; neither NexGard nor Simparica Trio have been evaluated in that population. BestiePaws.com™ strongly recommends this decision be made with your specific veterinarian, not from a general web comparison.
Comprehensive parasite prevention is genuinely medically necessary for most dogs in the United States — but whether Simparica Trio specifically is the right vehicle depends on your dog’s situation. What is necessary: Heartworm prevention is recommended year-round in all 50 U.S. states by the American Heartworm Society — the disease is fatal without aggressive (and expensive) treatment. Flea prevention protects against flea allergy dermatitis, tapeworm transmission, anemia in puppies, and Bartonella infection. Tick prevention protects against Lyme disease (CDC: most common vector-borne disease in the U.S.), Rocky Mountain spotted fever, ehrlichiosis, anaplasmosis, and more. What Simparica Trio offers that makes it convenient: combining all of the above into a single monthly pork-liver flavored chew — simplifying compliance, reducing the number of medications a dog owner manages, and lowering the risk of missed-dose protection gaps. Dogs for whom Simparica Trio may not be the best fit: those with seizure history, breeding females, dogs whose owners prefer topical options, or dogs in areas with very low tick prevalence where a simpler heartworm-only preventative might suffice. Always discuss the current regional parasite risk with your veterinarian when making this decision — parasite geography changes, and what was low-risk five years ago may not be today.
Sources: FDA fda.gov (Drug Safety Communication; isoxazoline fact sheet; tremors/ataxia/seizures; seizures without prior history; both NexGard and Simparica on same alert); Zoetis zoetispetcare.com (vomiting/diarrhea most common; no contraindications; 6 tick species; fleas 4hrs; not evaluated breeding/pregnant/lactating; 100% satisfaction guarantee; 1-888-963-8471); PMC 2020 Kryda et al. (≥96.2% flea reduction 8hrs; >95.6% monthly study 18 practices); BestiePaws.com™ bestiepaws.com (15M+ dogs Q4 2024; Asian longhorned tick Nov 2024; afoxolaner NexGard comparison; Bravecto breeding safety; 5 vs 6 tick species); DailyMed NIH (prescribing info: test for heartworm before starting; not adulticidal; pyrantel roundworm/hookworm); budgetpetworld.com Mar 2025 (minimum weights 2.8/4/4.4 lbs); American Heartworm Society (year-round prevention all 50 states); CDC (Lyme disease most common vector-borne disease U.S.)
- Have your dog tested for heartworm before the first dose. Simparica Trio does not treat adult heartworms. Giving it to a heartworm-positive dog without first clearing the adult worm burden can cause dangerous thromboembolic reactions. A simple blood antigen test at your vet — typically done at annual wellness visits — is required before starting. This is not optional: it is stated in the official prescribing information.
- Tell your vet about any history of seizures, epilepsy, or neurological conditions. The FDA’s formal Drug Safety Communication identifies seizure history as a risk factor for neurological adverse reactions with isoxazoline products. If your dog has ever had a seizure, tremors, or been diagnosed with epilepsy or any neurological disorder, explicitly discuss this before starting Simparica Trio. The vet may recommend an alternative without the isoxazoline class.
- Confirm your dog is not pregnant, in heat with a breeding plan, or lactating. Zoetis has not evaluated Simparica Trio’s safety in these populations. If your dog may become pregnant or is actively breeding, discuss alternatives (such as Bravecto, which has pregnancy safety data) with your vet.
- Keep it stored safely away from children. The pork-liver flavoring that makes it appealing to dogs also makes it potentially appealing to small children. Store in the original child-resistant packaging in a secure location. If a child accidentally ingests a tablet, call U.S. Poison Control immediately at 1-800-222-1222 — do not wait for symptoms.
- Know the signs of an adverse reaction and what to do. If your dog experiences vomiting or diarrhea within 24 hours of a dose, monitor closely — these are common and usually self-limiting. If your dog shows muscle tremors, stumbling, uncoordination, unresponsiveness, or has a seizure after taking Simparica Trio, contact your veterinarian immediately. You can also report adverse events to Zoetis at 1-888-963-8471 and to the FDA through the Safety Reporting Portal at safetyreporting.hhs.gov.
This guide is independently researched and written by BestiePaws.com™ for informational purposes only. BestiePaws.com™ is not affiliated with, compensated by, or endorsed by Zoetis, Inc., Boehringer Ingelheim, Merck Animal Health, or any pharmaceutical manufacturer. This content does not constitute veterinary medical advice. Always consult a licensed veterinarian before starting, changing, or stopping any medication for your dog. Simparica Trio® is a registered trademark of Zoetis Services LLC. All other product names mentioned are the property of their respective owners.
Primary sources: FDA fda.gov (NADA 141-521 approval Feb 27 2020; April 8 2025 supplement flea tapeworm; Drug Safety Communication isoxazoline neurological; fact sheet: tremors/ataxia/seizures; “seizures without prior history”; sarolaner first approved 2016; moxidectin 1997; pyrantel 1977; FDA considers products safe+effective majority dogs; fda.gov/animal-veterinary/animal-health-literacy/fact-sheet-pet-owners); DailyMed NIH dailymed.nlm.nih.gov (prescribing info NADA 141-521; sarolaner GABA/glutamate inhibition; moxidectin chloride channel; pyrantel GI nematocide; “use with caution seizure history”; no known contraindications; not evaluated breeding/pregnant/lactating; most frequent adverse reactions: vomiting and diarrhea); Zoetis zoetispetcare.com (pork-liver flavored; 6 tablet sizes; 6 tick species; fleas 4hrs; deer ticks 8hrs; not adulticidal; test required before starting; 100% satisfaction guarantee; $9.3B revenue 2024; 13,800 employees); Zoetis April 14 2025 press release (FDA new indication flea tapeworm April 14 2025; only combo parasiticide indicated for flea tapeworm prevention); Zoetis 2022 statement (isoxazoline class warning confirmed; label always included neuro signs); PMC 2023 Mathur et al. pmc.ncbi.nlm.nih.gov/PMC10064668 (well tolerated heartworm-positive 1×/3× dose; emesis low frequency; fever resolved 1 day 1/3 dose groups; no severe hypersensitivity); PMC 2020 Kryda et al. pmc.ncbi.nlm.nih.gov/PMC7049388 (18 U.S. practices; RCT; safe+efficacious natural flea infestations); PMC survey isoxazoline PMC7738705 (documented: tremors, decreased proprioception, ataxia, decreased/absent menace, seizures); BestiePaws.com™ bestiepaws.com (15M+ dogs Q4 2024; first combo isoxazoline U.S.; Asian longhorned tick Nov 2024 label expansion; 6 vs 5 vs 4 tick species NexGard/Credelio; praziquantel Credelio Quattro; Bravecto MDR1/breeding safety); budgetpetworld.com Mar 2025 (6 tick species Simparica Trio; NexGard 5; Bravecto 4; min weights 2.8/4/4.4 lbs); hardypaw.com Jun 2025 (Bravecto: MDR1-sensitive breeds safer; pregnant dogs safe); American Heartworm Society heartwormsociety.org (year-round prevention all 50 states); CDC (Lyme disease most common vector-borne disease U.S.); Poison Control 1-800-222-1222